12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vimizim elosulfase alfa regulatory update

BioMarin said FDA and EMA accepted for review regulatory applications for Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome). FDA granted Priority Review to the BLA, but the agency subsequently extended the PDUFA date by 3 months after...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >